Navigation Links
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
Date:4/28/2009

rk and a leading botulinum neurotoxin researcher.

The NT-201 data will be presented at the AAN's annual meeting. The data include poster p07.088, Efficacy and safety of NT-201 (Botulinum neurotoxin free from complexing proteins) in cervical dystonia, poster p07.081, Clinical efficacy in focal dystonia and overall tolerability of NT-201 (botulinum neurotoxin free from complexing proteins) and poster p07.091, Efficacy and safety of NT-201 (Botulinum neurotoxin free from complexing proteins) in Blepharospasm.

Joseph Jankovic, M.D. Professor of Neurology, Distinguished Chair in Movement Disorders, and Director of the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine in Houston and a lead investigator of the blepharospasm study noted that "these promising data indicate that following approval, Xeomin will become an important treatment option for movement disorders."

About the Studies

Efficacy and safety of NT-201 (Botulinum neurotoxin free from complexing proteins) in cervical dystonia. Presented by Cynthia Comella of Rush University in Chicago.

Method

This prospective, double-blind, placebo-controlled, multi-center study evaluated the safety and efficacy of NT-201 [Botulinum neurotoxin A (BoNT A) free from complexing proteins], compared to placebo in subjects with cervical dystonia (CD). There were 233 CD patients (66% women, age 52.8 years, CD duration 51.9 months), 39% not previously treated with BoNT. Patients were randomized to placebo (N= 74), 120 U NT-201 (N= 78), and 240U NT-201 (N= 81). Following injection, patients were evaluated at 4 weeks using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS); adverse events (AEs) were also collected. The primary outcome was the change from Baseline to week 4 for the TWSTRS-
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
2. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
3. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
7. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
8. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
9. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
10. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
11. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  Valeant Pharmaceuticals International, ... today announced that its affiliate has entered into ... was granted an exclusive license to develop and ... IL-17 receptor monoclonal antibody in development for patients ... the agreement, Valeant will hold the exclusive rights ...
(Date:8/31/2015)... , Aug. 31, 2015 Pepperl+Fuchs, a ... acquired MACTek Corporation, a leading provider of HART ... strategy to further extend its integrated solutions offerings ...   "We are pleased to add ... portfolio," said Jim Bolin , Pepperl+Fuchs, executive ...
(Date:8/31/2015)... , Aug. 31, 2015 Thousands of people ... neglect of the opioid addiction epidemic at dozens of ... term in 2008, the United States ... addiction involving prescription opioids and heroin, yet the President ... a strongly worded letter to President Obama , ...
Breaking Medicine Technology:Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
... Sept. 7 Epeius Biotechnologies Corporation, a leader in ... publication of a landmark paper in clinical oncology. Following ... of Rexin-G in chemo-resistant metastatic pancreatic cancer ( Molecular ... Drug and FDA Fast Track Status, this new paper ...
... India, Sept. 7 Sun Pharmaceutical Industries Ltd. (Sun) ... today announced that the Supreme Court of Israel has ... (Taro) (Pink Sheets: TAROF ) of the ... the Israeli special tender offer (STO) rules do not ...
Cached Medicine Technology:To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles' 2Supreme Court of Israel Rules in Favor of Sun Pharma 2Supreme Court of Israel Rules in Favor of Sun Pharma 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia entrepreneur Marcella Ellis, ... strongly maintaining her firm’s success in the hair care and distribution industry through ... tour, Ellis will be providing “Look and learn” live demonstrations, as well as ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... monitoring and analysis of pet vital signs and activity, today announced its integration ... of the most popular and widely-adopted veterinary hospital Practice Management Software packages in ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of data loss ... version of endpoint DLP developed specifically for Mac OS. , In June 2015, the ... IT and information security professionals had participated. The beta test done by the developer ...
(Date:9/1/2015)... ... 2015 , ... SC&H Group, a leading audit, tax, and consulting firm, received ... the Best” firm in the U.S., as well as being ranked a Top 100 ... the U.S., selected exclusively on performance in specific areas of financial and operational management. ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... approved a gel that promises less internal scarring ... initially rejected Lifecore Biomedical Inc.'s Intergel, which promises ... // ,The gel, formally named Gynecare ... adhesions, internal scar tissue that can cause chronic ...
... protein released by damaged heart tissue may be a helpful ... Performing heart bypass surgery or angioplasty on patients with elevated ... estimated 40 percent. ,// ,"Any sign of heart ... amount, was a sign that the patient was at high ...
... and aspirin are equally effective in stroke prevention in the ... stopping platelets from clumping together, while warfarin acts on the ... help prevent blood clots in the brain that lead to ... more effective at preventing stroke, but causes more side effects ...
... similar impact on the body to the ageing process ... such as heart disease and diabetes, researchers have found. ... asleep per night in more developed countries has decreased ... been made to accommodate increased demands of work and ...
... the first time, the US Food and Drug Administration (FDA) ... Evra, made by New Jersey-based Johnson & Johnson, is a ... to be an alternative to birth control pills. // ... a 1-week period. Ortho Evra can be worn on the ...
... have recently found a way of creating brain cells out ... grafts for Parkinson's disease. At the Peterson Medical College scientists ... cocktail of growth factors and other chemicals and found they ... such stem cells form muscle, bone, cartilage and fat. The ...
Cached Medicine News:Health News:Deprived sleep leads to ageing 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
Desmarres Lid Retractor thin solid blades. Size 2....
The Storz Protege is an anterior segment unit only....
... all the features of phaco systems costing ... minimal maintenance. Small, light and tough enough ... Lowest cost reusable tubing kit can be ... there a price objection to purchasing a ...
Medicine Products: